Skip to content

Interim report January – March 2024: PROPRIETARY SIMULATORS WEAK, INDUSTRIAL SEGMENT STRONG

FIRST QUARTER 2024 (JAN – MAR)

Net sales amounted to SEK 188.2 (229.1) million, a decrease of 18 percent compared with the corresponding period in the preceding year.

License revenue amounted to SEK 63.2 (70.6) million and accounted for 34 (31) percent of net sales.

The gross margin was 66 (69) percent.

Operating profit amounted to SEK 26.0 (53.3) million.

Net profit amounted to SEK 23.8 (49.8) million, corresponding to earnings per share of SEK 0.47 (0.98).

Cash flow from operating activities amounted to SEK 28.5 (60.5) million. As of March 31, 2024, cash and cash equivalents amounted to SEK 659.2 (482.1) million.

Gothenburg, Sweden, May 15, 2024
Surgical Science Sweden AB (publ)

This report, in its entirety, is available through the attachment or via:
https://surgicalscience.com/aktien/pressmeddelanden/
https://surgicalscience.com/aktien/finansiella-rapporter/

This is a translation of the Swedish version of the interim report. When in doubt, the Swedish wording prevails.

Skip to navigation